论文部分内容阅读
建议内容:省十二届人大一次会议期间,常德代表团肖汉族代表提出《关于助推我省生物医药产业快速发展的建议》(编号第1692号)。建议指出,2012年全省生物医药工业总产值预计超过600亿元,成为我省七大战略性新共产业之一。但随着药品监管力度不断加强,生物医药产业正面临着巨大的挑战:1、国务院已明确规定所有无菌药品和医疗器械生产企业要在2013年底前,非无菌药品和医疗器械生产企业要在2015年底前全面通过新修订的《药品生产质量管理规范》(以下简称药品GMP认证),预计全省225家生产企业须投入70亿元的资金用于新修订的GMP改造,大部分企业资金短缺。但如果在限期内没通过认证,企业将被淘汰。2、我省生
Suggestions: During the first meeting of the 12th National People’s Congress of the province, the representative of Xiaohan of Changde delegation proposed “Proposal on Boosting the Rapid Development of Biomedicine Industry in Our Province” (No. 1692). The suggestion pointed out that in 2012 the province’s biomedical industry output is expected to exceed 600 billion yuan, becoming one of the province’s seven strategic new communist industries. However, with the continuous strengthening of drug regulatory efforts, the biopharmaceutical industry is facing enormous challenges: 1. The State Council has clearly stipulated that all manufacturers of sterile and medical devices should have non-sterile pharmaceutical and medical device manufacturers by the end of 2013 By the end of 2015, the newly revised “Good Manufacturing Practices for Pharmaceutical Production” (hereinafter referred to as “GMP”) is expected to require 225 manufacturing enterprises in the province to invest 7 billion yuan for the newly revised GMP reform. Most of the corporate funds shortage. However, if you fail to pass the certification within the deadline, the company will be eliminated. 2, our province students